FFECT OF LIRAGLUTIDE ON CARDIOVASCULAR RISK FACTORS AND FUNCTION
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2011, Vol 18, Issue 3
Abstract
Cardiovascular disease is the major cause of death in diabetes. This results from a cluster of risk factors, including high glucose, obesity, hypertension and dyslipidaemia. Liraglutide is the first native GLP-1 analogue and represents a breakthrough approach in type 2 diabetes treatment. Previous data from the LEAD™ programme have shown liraglutide to be a potent glucose regulator, but also to induce weight loss, lower blood pressure, and potentially show improvements in lipid levels, amongst other markers of cardiovascular risk. GLP-1 has also been shown to have an effect on the renal system, as well as the vascular system. Other cardio-protective effects of GLP-1 were proved in animal models: improves cardiac function in heart failure, functional recovery following myocardial ischemia, endothelium dysfunction, increases myocardial glucose uptake and reduces infarct size. Cardiovascular safety of liraglutide was assessed using existing clinical data. The incidence ratio for adjudicated broad/serious major adverse cardiovascular events (MACE) associated with liraglutide was 0.73 (95% CI 0.38–1.41) versus all comparator drugs, within cardiovascular safety limits defined by the United States Food & Drug Administration.
Authors and Affiliations
Maria Mota, Emiliana Mocan, Sorina Botescu
Keywords
Related Articles
- EP ID EP113933
- DOI -
- Views 111
- Downloads 0
CONSEQUENCES OF ADVANCES GLYCATION END PRODUCTS ACCUMULATION AND CLINICAL USEFULNESS OF THEIR ASSESSMENT USING A NON-INVASIVE TECHNIQUE
Accelerated formation and accumulation of advanced glycation end-products (AGEs) occur under circumstances of increased supply of substrates such as hyperglycaemic or oxidative stress and in age-related and chronic disea...
METABOLIC SYNDROME – THE "SILENT KILLER", A CONTINUING CHALLENGE
Metabolic syndrome, also known as dysmetabolic/plurimetabolic syndrome, X syndrome, insulinresistance syndrome or deadly quartet is an aggregate of interrelated metabolic abnormalities that occur with a higher prevalence...
THE VALUE OF DIFFERENT ANTHROPOMETRIC VARIABLES IN ASSESSING CARDIOMETABOLIC RISK
Objective. To investigate which anthropometric parameter best correlates with modifications in blood glucose and blood pressure (BP). Material and method. 135 subjects were included in the study. We measured weight, heig...
RESISTIN AND HIGH GLUCOSE CONCENTRATIONS-ACTIVATION OF HUMAN SMOOTH MUSCLE CELLS INDUCES ENHANCED MONOCYTE CHEMOTAXIS
EPIDEMIOLOGICAL CHARACTERISTICS OF METABOLIC SYNDROME IN THE POPULATION OF HUNEDOARA COUNTY
The metabolic syndrome (MS) is an association of proatherogenic clinical and biochemical abnormalities, that is considered to contribute to the epidemic of diabetes mellitus and cardiovascular diseases. In this study, we...